Chalazion associated with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database

Authors

Harkarandeep Singh, Rochester Regional HealthFollow
Uttamjot Kaur, Dayanand Medical College, Ludhiana, India
Niraj Neupane, Rochester Regional HealthFollow
Hasaan Saeed, Rochester Regional HealthFollow
Himal Kharel, Rochester Regional HealthFollow
Prabhsimrat Gill, Rochester Regional HealthFollow
Asis Shrestha, University of Arkansas for Medical Sciences, Little Rock, AR

Department

Internal Medicine

Document Type

Conference Proceeding

Publication Title

Journal of Clinical Oncology

Conference Name

American Society of Clinical Oncology (ASCO) Annual Meeting

Conference Date

2024-05-31 - 2024-06-04

First Page

e23325

DOI

10.1200/JCO.2024.42.16_suppl.e23325

Volume

42

Issue

16_suppl

Publication Date

6-1-2024

Recommended Citation

Singh, H., Kaur, U., Neupane, N., Saeed, H., Kharel, H., Gill, P., & Shrestha, A. (2024). Chalazion associated with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database. Journal of Clinical Oncology, 42 (16_suppl), e23325. https://doi.org/10.1200/JCO.2024.42.16_suppl.e23325